The Snus Paradox: The World's Most Successful Harm Reduction Product Is Banned Almost Everywhere

The most successful tobacco harm reduction product in history is illegal in 26 of the 27 European Union member states. Swedish snus—a moist oral tobacco product placed under the upper lip—has been used in Sweden for over 200 years. It is associated with a small increased risk of pancreatic cancer (the evidence is inconsistent), no increased risk of lung cancer or cardiovascular disease (unlike cigarettes), and no evidence of the oral cancers that are associated with American chewing tobacco and South Asian smokeless products. The epidemiological evidence from Sweden—where snus use largely replaced cigarette smoking among men over the course of the 20th century—is among the strongest evidence in all of public health for the harm reduction potential of non-combustible nicotine products. And yet: snus has been banned in the EU since 1992, with Sweden granted a permanent exemption upon joining the EU in 1995. The ban is not based on evidence of harm. It is based on a precautionary principle that the evidence has comprehensively refuted.

The Swedish data is not subtle. Swedish men smoke at the lowest rate in Europe (approximately 5% daily smoking) but use nicotine at European-average rates (approximately 20% of men use snus daily). The substitution of snus for cigarettes has produced the lowest male lung cancer mortality rate in Europe, the lowest male oral cancer mortality rate in Europe, and a male life expectancy that is among the highest in Europe. Swedish women, who adopted snus later and in smaller numbers, have smoking rates comparable to other European countries—and lung cancer mortality to match. The natural experiment is as clean as epidemiology ever gets: a population where a large proportion of nicotine users switched from combustible to non-combustible products, and where the health outcomes reflect the switch. The evidence is not ambiguous. It is not contested (the basic epidemiological facts are accepted by all parties). It is simply ignored by the policy framework that maintains the EU ban.

The EU ban on snus, formalized in the 1992 Tobacco Products Directive and reaffirmed in subsequent revisions, has never been justified by a systematic review of the evidence on snus and health. The ban's origin is historical and political, not scientific. When the EU was harmonizing tobacco product regulations in the early 1990s, snus was an unfamiliar product in most member states, and the precautionary approach—ban it unless proven safe—prevailed. The evidence that has accumulated since 1992—including large-scale Swedish cohort studies, a comprehensive 2018 review by the UK Royal College of Physicians, and multiple analyses by the Norwegian Institute of Public Health (Norway is not in the EU and has legal snus)—has demonstrated that the precautionary approach was wrong. But the EU's regulatory machinery, once set in motion, is difficult to reverse. The ban remains in place not because the evidence supports it, but because no political constituency has the incentive and the power to overturn it.

The consequences of the EU snus ban are measurable. A modeling study published in the European Journal of Public Health in 2021 estimated that if snus had been legalized across the EU in 1992, approximately 350,000 premature deaths would have been avoided by 2020—primarily among men who would have switched from cigarettes to snus but did not have access to the product. The estimate is model-dependent and should be treated as approximate, but the direction of the effect is unambiguous. The EU's precautionary approach—banning a product that subsequent evidence showed to be dramatically safer than cigarettes—has cost lives. This is not a hypothetical concern. It is a quantifiable public health failure, and the institutions responsible for it have never been held accountable.

The snus experience has direct relevance to contemporary debates about vaping, nicotine pouches, and heated tobacco. All three product categories face regulatory opposition based on the same precautionary logic that underpinned the EU snus ban: they are new, their long-term effects are unknown, the industry that produces them cannot be trusted, and they might serve as a gateway to smoking rather than an off-ramp from it. The snus experience demonstrates that the precautionary approach can be spectacularly wrong—that banning a product whose risks are unknown can result in the continued use of a product whose risks are known and catastrophic. The burden of proof, in the precautionary framework, always falls on the new product to demonstrate safety. The existing product—cigarettes—is never required to justify its continued availability. The asymmetry is logically indefensible, but it is deeply embedded in the institutional culture of tobacco regulation.

The snus paradox—the world's most successful harm reduction product, banned almost everywhere—is a cautionary tale about the relationship between evidence and policy. The evidence that a policy is harmful does not guarantee that the policy will be changed. Institutional inertia, political economy, and the career incentives of the people who designed and defended the policy all resist change. The snus ban has been in place for over thirty years. The evidence against it has been accumulating for most of that time. The ban persists. The lesson for contemporary nicotine policy is sobering: building an evidence base to support harm reduction is necessary but not sufficient. The evidence matters only if there is a political constituency willing and able to act on it. In the EU, on snus, there is not.

Shareable insight: Sweden has Europe's lowest smoking rate and lowest lung cancer mortality—because Swedish men use snus instead of cigarettes. Snus has been banned in the rest of the EU since 1992, on precautionary grounds, and an estimated 350,000 people have died prematurely as a result. The evidence was right. The policy was wrong. The policy is still in place.